Abdul Rashid Qureshi

Dr. Abdul Rashid Qureshi

Karolinska Institutet
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
NINaohito Isoyama
Naohito Isoyama
AQAbdul Rashid Qureshi
Abdul Rashid Qureshi
CACarla Maria Avesani
Carla Maria Avesani
BLBengt Lindholm
Bengt Lindholm
PBPeter Bàràny
Peter Bàràny
JCJuan Jesús Carrero
Juan Jesús Carrero
Background and objectives Reduced muscle mass and strength are prevalent conditions in dialysis patients. However, muscle strength and muscle mass are not congruent; muscle strength can diminish even though muscle mass is maintained or increased. This study addresses phenotype and mortality associations of these muscle dysfunction entities alone or in combination (i.e., concurrent loss of muscle mass and strength/mobility, here defined as sarcopenia). Design, setting, participants, & measurements This study included 330 incident dialysis patients (203 men, mean age 53±13 years, and mean GFR 7±2 ml/min per 1.73 m2) recruited between 1994 and 2010 and followed prospectively for up to 5 years. Low muscle mass (by dual-energy x-ray absorptiometry appendicular mass index) and low muscle strength (by handgrip) were defined against young reference populations according to the European Working Group on Sarcopenia in Older People. Results Whereas 20% of patients had sarcopenia, low muscle mass and low muscle strength alone were observed in a further 24% and 15% of patients, respectively. Old age, comorbidities, protein-energy wasting, physical inactivity, low albumin, and inflammation associated with low muscle strength, but not with low muscle mass (multivariate ANOVA interactions). During follow-up, 95 patients (29%) died and both conditions associated with mortality as separate entities. When combined, individuals with low muscle mass alone were not at increased risk of mortality (adjusted hazard ratio [HR], 1.23; 95% confidence interval [95% CI], 0.56 to 2.67). Individuals with low muscle strength were at increased risk, irrespective of their muscle stores being appropriate (HR, 1.98; 95% CI, 1.01 to 3.87) or low (HR, 1.93; 95% CI, 1.01 to 3.71). Conclusions Low muscle strength was more strongly associated with aging, protein-energy wasting, physical inactivity, inflammation, and mortality than low muscle mass. Assessment of muscle functionality may provide additional diagnostic and prognostic information to muscle-mass evaluation.

1 March 1998 in Kidney International
Verified
Journal Article
Closed access
AQAbdul Rashid Qureshi
Abdul Rashid Qureshi
AAAnders Alvestrand
Anders Alvestrand
ADAnders Danielsson
Anders Danielsson
JDJosé C. Divino-Filho
José C. Divino-Filho
AGAlberto Gutierrez
Alberto Gutierrez
JBJonas Bergström
Jonas Bergström

1 January 2006 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
HHHirokazu Honda
Hirokazu Honda
AQAbdul Rashid Qureshi
Abdul Rashid Qureshi
OHOlof Heimbürger
Olof Heimbürger
PBPeter Barany
Peter Barany
KWKai Wang
Kai Wang
BLBengt Lindholm
Bengt Lindholm

30 January 2007 in Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
PSPeter Stenvinkel
Peter Stenvinkel
MKM. Karimi
M. Karimi
SJS. Johansson
S. Johansson
JAJ. Axelsson
J. Axelsson
MSM. Suliman
M. Suliman
MSM. Schalling
M. Schalling
: Objective.  The lifespan of dialysis patients is as short as in patients with metastatic cancer disease, mainly due to cardiovascular disease (CVD). DNA methylation is an important cellular mechanism modulating gene expression associated with ageing, inflammation and atherosclerotic processes.Design.  DNA methylation was analysed in peripheral blood leucocytes from three different groups of chronic kidney disease (CKD) populations (37 CKD stages 3 and 4 patients, 98 CKD stage 5 patients and 20 prevalent haemodialysis patients). Thirty‐six healthy subjects served as controls. Clinical characteristics (diabetes mellitus, nutritional status and presence of clinical CVD), inflammation and oxidative stress biomarkers, homocysteine and global DNA methylation in peripheral blood leucocytes (defined as HpaII/MspI ratio by the Luminometric Methylation Assay method) were evaluated. CKD stage 5 patients (n = 98) starting dialysis treatment were followed for a period of 36 ± 2 months.Results.  Inflamed patients had lower ratios of HpaII/MspI, indicating global DNA hypermethylation. Analysis by the Cox regression model demonstrated that DNA hypermethylation (HpaII/MspI ratio <median) was significantly associated with both all‐cause (RR 5.0; 95% CI: 1.7–14.8; P < 0.01) and cardiovascular (RR 13.9; 95% CI: 1.8–109.3; P < 0.05) mortality, even following the adjustment for age, CVD, diabetes mellitus and inflammation.Conclusion.  The present study demonstrates that global DNA hypermethylation is associated with inflammation and increased mortality in CKD.

11 January 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CMCatharina Missailidis
Catharina Missailidis
JHJenny Hällqvist
Jenny Hällqvist
AQAbdul Rashid Qureshi
Abdul Rashid Qureshi
PBPeter Barany
Peter Barany
OHOlof Heimbürger
Olof Heimbürger
PBPeter Bergman
Peter Bergman
The microbial metabolite Trimethylamine-N-oxide (TMAO) has been linked to adverse cardiovascular outcome and mortality in the general population. To assess the contribution of TMAO to inflammation and mortality in chronic kidney disease (CKD) patients ranging from mild-moderate to end-stage disease and 1) associations with glomerular filtration rate (GFR) 2) effect of dialysis and renal transplantation (Rtx) 3) association with inflammatory biomarkers and 4) its predictive value for all-cause mortality. Levels of metabolites were quantified by a novel liquid chromatography/tandem mass spectrometry-based method in fasting plasma samples from 80 controls and 179 CKD 3–5 patients. Comorbidities, nutritional status, biomarkers of inflammation and GFR were assessed. GFR was the dominant variable affecting TMAO (β = -0.41; p<0.001), choline (β = -0.38; p<0.001), and betaine (β = 0.45; p<0.001) levels. A longitudinal study of 74 CKD 5 patients starting renal replacement therapy demonstrated that whereas dialysis treatment did not affect TMAO, Rtx reduced levels of TMAO to that of controls (p<0.001). Following Rtx choline and betaine levels continued to increase. In CKD 3–5, TMAO levels were associated with IL-6 (Rho = 0.42; p<0.0001), fibrinogen (Rho = 0.43; p<0.0001) and hsCRP (Rho = 0.17; p = 0.022). Higher TMAO levels were associated with an increased risk for all-cause mortality that remained significant after multivariate adjustment (HR 4.32, 95% CI 1.32–14.2; p = 0.016). Elevated TMAO levels are strongly associated with degree of renal function in CKD and normalize after renal transplantation. TMAO levels correlates with increased systemic inflammation and is an independent predictor of mortality in CKD 3–5 patients.

1 June 2008 in The American Journal of Clinical Nutrition
Verified
Journal Article
Open access
PDF file
MWMakoto Watanabe
Makoto Watanabe
MSMohamed E Suliman
Mohamed E Suliman
AQAbdul Rashid Qureshi
Abdul Rashid Qureshi
EGElvia Garcia-Lopez
Elvia Garcia-Lopez
PBPeter Barany
Peter Barany
BLBengt Lindholm
Bengt Lindholm
Background: Histidine is considered as an antiinflammatory and antioxidant factor. Histidine deficiency may contribute to an impaired nutritional state in patients with chronic kidney disease (CKD). Objective: We aimed to investigate the consequences of plasma histidine deficiency in CKD patients. Design: CKD patients (n = 325; 203 M) with a median age of 54 y (range: 19–70 y) were evaluated shortly before the beginning of renal replacement therapy. The median glomerular filtration rate was 6.4 mL/min (range: 0.8–14.5 mL/min). Nutritional status was assessed by subjective global assessment. Survival was followed for up to 60 mo; 101 patients died. Results: Plasma histidine concentrations were significantly lower in CKD patients with history of cardiovascular disease, presence of plaques, protein-energy wasting, and inflammation. Plasma histidine was negatively associated with age, C-reactive protein, interleukin-6, leukocytes, thrombocytes, fibrinogen, hepatocyte growth factor, adhesion molecules, insulin-like growth factor-1, and 8-hydroxy-2′-deoxyguanosine and was positively associated with handgrip strength, hemoglobin, S-albumin and fetuin-A. A multivariate regression analysis showed that histidine concentrations were independently associated with hepatocyte growth factor, hemoglobin, and fetuin-A. In unadjusted analysis, a low histidine concentration was associated with all-cause mortality (log rank chi-square test = 8.9; P = 0.002). After adjustment for age, sex, cardiovascular disease, inflammation, diabetes mellitus, serum S-albumin, and amino acid supplementation, the association between low histidine and mortality remained significant (hazard ratio: 1.55; 95% CI: 1.02, 2.40; P < 0.05). Conclusion: Low plasma concentrations of histidine are associated with protein-energy wasting, inflammation, oxidative stress, and greater mortality in CKD patients.